Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder

(RUPP), R. U. O. P. P. (2005). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry, 62(11), 1266–1274. https://doi.org/10.1001/archpsyc.62.11.1266CrossRef

Adler, B. A., Wink, L. K., Early, M., Shaffer, R., Minshawi, N., McDougle, C. J., & Erickson, C. A. (2015). Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: A chart review study. Autism, 19(1), 102–106. https://doi.org/10.1177/1362361314524641CrossRefPubMed

Aman, M. G., Findling, R. L., Hardan, A. Y., Hendren, R. L., Melmed, R. D., Kehinde-Nelson, O., & Katz, E. (2017). Safety and efficacy of memantine in children with autism: Randomized, placebo-controlled study and open-label extension. Journal of Child and Adolescent Psychopharmacology, 27(5), 403–412. https://doi.org/10.1089/cap.2015.0146CrossRefPubMedPubMedCentral

Anagnostou, E., Aman, M. G., Handen, B. L., Sanders, K. B., Shui, A., Hollway, J. A., & Veenstra-VanderWeele, J. (2016). Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: A randomized clinical trial. JAMA Psychiatry, 73(9), 928–937. https://doi.org/10.1001/jamapsychiatry.2016.1232CrossRefPubMed

Anagnostou, E., Soorya, L., Chaplin, W., Bartz, J., Halpern, D., Wasserman, S., & Hollander, E. (2012). Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: A randomized controlled trial. Molecular Autism, 3(1), 16. https://doi.org/10.1186/2040-2392-3-16CrossRefPubMedPubMedCentral

Aoki, Y., Watanabe, T., Abe, O., Kuwabara, H., Yahata, N., Takano, Y., & Yamasue, H. (2015). Oxytocin’s neurochemical effects in the medial prefrontal cortex underlie recovery of task-specific brain activity in autism: A randomized controlled trial. Molecular Psychiatry, 20(4), 447–453. https://doi.org/10.1038/mp.2014.74CrossRefPubMed

Appleton, R. E., Jones, A. P., Gamble, C., Williamson, P. R., Wiggs, L., Montgomery, P., & Gringras, P. (2012). The use of MElatonin in children with neurodevelopmental disorders and impaired sleep: A randomised, double-blind, placebo-controlled, parallel study (MENDS). Health Technology Assessment, 16(40), i239. https://doi.org/10.3310/hta16400CrossRef

Aran, A., Cassuto, H., Lubotzky, A., Wattad, N., & Hazan, E. (2019). Brief Report: Cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems—a retrospective feasibility study. Journal of Autism and Developmental Disorders, 49(3), 1284–1288. https://doi.org/10.1007/s10803-018-3808-2CrossRefPubMed

Arnold, B., Elliott, A., Laohamroonvorapongse, D., Hanna, J., Norvell, D., & Koh, J. (2015). Autistic children and anesthesia: Is their perioperative experience different? Paediatric Anaesthesia, 25(11), 1103–1110. https://doi.org/10.1111/pan.12739CrossRefPubMed

Arnold, L. E., Aman, M. G., Cook, A. M., Witwer, A. N., Hall, K. L., Thompson, S., & Ramadan, Y. (2006). Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial. Journal of the American Academy of Child and Adolescent Psychiatry, 45(10), 1196–1205. https://doi.org/10.1097/01.chi.0000231976.28719.2aCrossRefPubMed

Bachenberg, K. L. (1998). Oral ketamine for the management of combative autistic adult. Anesthesiology, 89(2), 549–550.CrossRef

Barchel, D., Stolar, O., De-Haan, T., Ziv-Baran, T., Saban, N., Fuchs, D. O., & Berkovitch, M. (2018). Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities. Frontiers in Pharmacology, 9, 1521. https://doi.org/10.3389/fphar.2018.01521CrossRefPubMed

Bar-Lev Schleider, L., Mechoulam, R., Saban, N., Meiri, G., & Novack, V. (2019). Real life experience of medical cannabis treatment in autism: Analysis of safety and efficacy. Science Reports, 9(1), 200. https://doi.org/10.1038/s41598-018-37570-yCrossRef

Beherec, L., Lambrey, S., Quilici, G., Rosier, A., Falissard, B., & Guillin, O. (2011). Retrospective review of clozapine in the treatment of patients with autism spectrum disorder and severe disruptive behaviors. Journal of Clinical Psychopharmacology, 31(3), 341–344. https://doi.org/10.1097/JCP.0b013e318218f4a1CrossRefPubMed

Bernaerts, S., Boets, B., Bosmans, G., Steyaert, J., & Alaerts, K. (2020). Behavioral effects of multiple-dose oxytocin treatment in autism: A randomized, placebo-controlled trial with long-term follow-up. Molecular Autism, 11(1), 6. https://doi.org/10.1186/s13229-020-0313-1CrossRefPubMedPubMedCentral

Berry-Kravis, E., Hagerman, R., Visootsak, J., Budimirovic, D., Kaufmann, W. E., Cherubini, M., & Carpenter, R. L. (2017). Arbaclofen in fragile X syndrome: Results of phase 3 trials. Journal of Neurodevelopmental Disorders, 9, 3. https://doi.org/10.1186/s11689-016-9181-6CrossRefPubMedPubMedCentral

Berry-Kravis, E. M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K., & Hagerman, R. J. (2012). Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized, controlled, phase 2 trial. Science Translational Medicine, 4(152), 152–127. https://doi.org/10.1126/scitranslmed.3004214CrossRef

Blackmer, A. B., & Feinstein, J. A. (2016). Management of sleep disorders in children with neurodevelopmental disorders: A review. Pharmacotherapy, 36(1), 84–98. https://doi.org/10.1002/phar.1686CrossRefPubMed

Bolognani, F., Del Valle Rubido, M., Squassante, L., Wandel, C., Derks, M., Murtagh, L., & Fontoura, P. (2019). A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. Science Translational Medicine, 11(491), 7838. https://doi.org/10.1126/scitranslmed.aat7838CrossRef

Bottema-Beutel, K., Kapp, S., Lester, J., Sasson, N., & Hand, B. (2021). Avoiding Ableist language: Suggestions for autism researchers. Autism in Adulthood, 3(1), 18–29. https://doi.org/10.1089/aut.2020.0014CrossRef

Braam, W., Ehrhart, F., Maas, A., Smits, M. G., & Curfs, L. (2018). Low maternal melatonin level increases autism spectrum disorder risk in children. Research in Developmental Disabilities. https://doi.org/10.1016/j.ridd.2018.02.017CrossRefPubMed

Brondino, N., Fusar-Poli, L., Panisi, C., Damiani, S., Barale, F., & Politi, P. (2016). Pharmacological modulation of GABA function in autism spectrum disorders: A systematic review of human studies. Journal of Autism and Developmental Disorders, 46(3), 825–839. https://doi.org/10.1007/s10803-015-2619-yCrossRefPubMed

Brown, J. J., Gray, J. M., Roback, M. G., Sethuraman, U., Farooqi, A., & Kannikeswaran, N. (2019). Procedural sedation in children with autism spectrum disorders in the emergency department. American Journal of Emergency Medicine, 37(8), 1404–1408. https://doi.org/10.1016/j.ajem.2018.10.025CrossRef

Campbell, C. T., Phillips, M. S., & Manasco, K. (2017). Cannabinoids in pediatrics. The Journal of Pediatric Pharmacology and Therapeutics, 22(3), 176–185. https://doi.org/10.5863/1551-6776-22.3.176CrossRefPubMedPubMedCentral

Canitano, R. (2005). Clinical experience with Topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders. Brain and Development, 27(3), 228–232. https://doi.org/10.1016/j.braindev.2004.06.006CrossRefPubMed

Ceylan, M. F., Erdogan, B., Tural Hesapcioglu, S., & Cop, E. (2017). Effectiveness, adverse effects and drug compliance of long-acting injectable risperidone in children and adolescents. Clinical Drug Investigation, 37(10), 947–956. https://doi.org/10.1007/s40261-017-0555-7CrossRefPubMed

Chez, M. G., Burton, Q., Dowling, T., Chang, M., Khanna, P., & Kramer, C. (2007). Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: An observation of initial clinical response and maintenance tolerability. Journal of Child Neurology, 22(5), 574–579. https://doi.org/10.1177/0883073807302611CrossRefPubMed

Ching, H., & Pringsheim, T. (2012). Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Systematic Reviews, 5, CD009043. https://doi.org/10.1002/14651858.CD009043.pub2CrossRef

Consensus development conference on antipsychotic drugs and obesity and diabetes. (2004). Diabetes Care, 27(2), 596–601.

Corson, A. H., Barkenbus, J. E., Posey, D. J., Stigler, K. A., & McDougle, C. J. (2004). A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. The Journal of Clinical Psychiatry, 65(11), 1531–1536. https://doi.org/10.4088/jcp.v65n1115CrossRefPubMed

Cortesi, F., Giannotti, F., Sebastiani, T., Panunzi, S., & Valente, D. (2012). Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: A randomized placebo-controlled trial. Journal of Sleep Research, 21(6), 700–709. https://doi.org/10.1111/j.1365-2869.2012.01021.xCrossRefPubMed

Coskun, M., Karakoc, S., Kircelli, F., & Mukaddes, N. M. (2009). Effectiveness of mirtazapine in the treatment of inappropriate sexual behaviors in individuals with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 19(2), 203–206. https://doi.org/10.1089/cap.2008.020CrossRefPubMed

Crutel, V., Lambert, E., Penelaud, P. F., Albarrán Severo, C., Fuentes, J., Rosier, A., & Falissard, B. (2020). Bumetanide oral liquid formulation for the treatment of children and adolescents with autism spectrum disorder: Design of two phase III studies (SIGN Trials). Journal of Autism and Developmental Disorders. https://doi.org/10.1007/s10803-020-04709-8CrossRefPubMedCentral

Cuomo, B. M., Vaz, S., Lee, E. A. L., Thompson, C., Rogerson, J. M., & Falkmer, T. (2017). Effectiveness of sleep-based interventions for children with autism spectrum disorder: A meta-synthesis. Pharmacotherapy, 37(5), 555–578. https://doi.org/10.1002/phar.1920CrossRefPubMed

Dadds, M. R., MacDonald, E., Cauchi, A., Williams, K., Levy, F., & Brennan, J. (2014). Nasal oxytocin for social deficits in childhood autism: A randomized controlled trial. Journal of Autism and Developmental Disorders, 44(3), 521–531. https://doi.org/10.1007/s10803-013-1899-3CrossRefPubMed

De Leersnyder, H., Zisapel, N., & Laudon, M. (2011). Prolonged-release melatonin for children with neurodevelopmental disorders. Pediatric Neurology, 45(1), 23–26. https://doi.org/10.1016/j.pediatrneurol.2011.02.001CrossRefPubMed

Dean, O. M., Gray, K. M., Villagonzalo, K. A., Dodd, S., Mohebbi, M., Vick, T., & Berk, M. (2017). A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder. Australian and New Zealand Journal of Psychiatry, 51(3), 241–249. https://doi.org/10.1177/0004867416652735CrossRef

Dominick, K., Wink, L. K., McDougle, C. J., & Erickson, C. A. (2015). A retrospective naturalistic study of ziprasidone for irritability in youth with autism spectrum disorder. Journal of Child and Adolescent Psychopharmacology, 25(5), 397–401. https://doi.org/10.1089/cap.2014.0111CrossRefPubMedPubMedCentral

Erickson, C. A., Posey, D. J., Stigler, K. A., Mullett, J., Katschke, A. R., & McDougle, C. J. (2007). A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (berl), 191(1), 141–147. https://doi.org/10.1007/s00213-006-0518-9CrossRef

Erickson, C. A., Veenstra-Vanderweele, J. M., Melmed, R. D., McCracken, J. T., Ginsberg, L. D., Sikich, L., & King, B. H. (2014). STX209 (arbaclofen) for autism spectrum disorders: An 8-week open-label study. Journal of Autism and Developmental Disorders, 44(4), 958–964. https://doi.org/10.1007/s10803-013-1963-zCrossRefPubMed

Fankhauser, M. P., Karumanchi, V. C., German, M. L., Yates, A., & Karumanchi, S. D. (1992). A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. The Journal of Clinical Psychiatry, 53(3), 77–82.PubMed

Fido, A., & Al-Saad, S. (2008). Olanzapine in the treatment of behavioral problems associated with autism: An open-label trial in Kuwait. Medical Principles and Practice, 17(5), 415–418. https://doi.org/10.1159/000141508CrossRefPubMed

Findling, R. L., McNamara, N. K., Gracious, B. L., O’Riordan, M. A., Reed, M. D., Demeter, C., & Blumer, J. L. (2004). Quetiapine in nine youths with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 14(2), 287–294. https://doi.org/10.1089/1044546041649129CrossRefPubMed

Fleury-Teixeira, P., Caixeta, F. V., Ramires da Silva, L. C., Brasil-Neto, J. P., & Malcher-Lopes, R. (2019). Effects of CBD-enriched cannabis sativa extract on autism spectrum disorder symptoms: An Observational study of 18 participants undergoing compassionate use. Frontiers in Neurology, 10, 1145. https://doi.org/10.3389/fneur.2019.01145CrossRefPubMedPubMedCentral

Fortea, A., Ilzarbe, D., Espinosa, L., Solerdelcoll, M., de Castro, C., Oriolo, G., & Baeza, I. (2018). Long-acting injectable atypical antipsychotic use in adolescents: An observational study. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2017.0096CrossRefPubMed

Frogley, C., Taylor, D., Dickens, G., & Picchioni, M. (2012). A systematic review of the evidence of clozapine’s anti-aggressive effects. The International Journal of Neuropsychopharmacology, 15(9), 1351–1371. https://doi.org/10.1017/s146114571100201xCrossRefPubMed

Frye, R. E. (2014). Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder. Drug, Healthcare and Patient Safety, 6, 69–76. https://doi.org/10.2147/dhps.s39595CrossRefPubMedPubMedCentral

Frye, R. E., Vassall, S., Kaur, G., Lewis, C., Karim, M., & Rossignol, D. (2019). Emerging biomarkers in autism spectrum disorder: A systematic review. Annals of Translational Medicine, 7(23), 792. https://doi.org/10.21037/atm.2019.11.53CrossRefPubMedPubMedCentral

Fusar-Poli, L., Cavone, V., Tinacci, S., Concas, I., Petralia, A., Signorelli, M. S., & Aguglia, E. (2020). Cannabinoids for people with ASD: A systematic review of published and ongoing studies. Brain Sciences, 10(9), 572. https://doi.org/10.3390/brainsci10090572CrossRefPubMedCentral

Gencer, O., Emiroglu, F. N., Miral, S., Baykara, B., Baykara, A., & Dirik, E. (2008). Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study. European Child & Adolescent Psychiatry, 17(4), 217–225. https://doi.org/10.1007/s00787-007-0656-6CrossRef

Goldani, A. A., Downs, S. R., Widjaja, F., Lawton, B., & Hendren, R. L. (2014). Biomarkers in autism. Frontiers in Psychiatry, 5, 100. https://doi.org/10.3389/fpsyt.2014.00100CrossRefPubMedPubMedCentral

Golubchik, P., Sever, J., & Weizman, A. (2011). Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: Open-label trial. Clinical Neuropharmacology, 34(6), 216–219. https://doi.org/10.1097/WNF.0b013e31823349acCrossRefPubMed

Gringras, P., Gamble, C., Jones, A. P., Wiggs, L., Williamson, P. R., Sutcliffe, A., & Appleton, R. (2012). Melatonin for sleep problems in children with neurodevelopmental disorders: Randomised double masked placebo controlled trial. BMJ, 345, e6664. https://doi.org/10.1136/bmj.e6664CrossRefPubMedPubMedCentral

Gringras, P., Nir, T., Breddy, J., Frydman-Marom, A., & Findling, R. L. (2017). Efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 56(11), 948-957.e944. https://doi.org/10.1016/j.jaac.2017.09.414CrossRefPubMed

Hadjikhani, N., Åsberg Johnels, J., Lassalle, A., Zürcher, N. R., Hippolyte, L., Gillberg, C., & Ben-Ari, Y. (2018). Bumetanide for autism: More eye contact, less amygdala activation. Science Reports, 8(1), 3602. https://doi.org/10.1038/s41598-018-21958-xCrossRef

Hadjikhani, N., Zürcher, N. R., Rogier, O., Ruest, T., Hippolyte, L., Ben-Ari, Y., & Lemonnier, E. (2015). Improving emotional face perception in autism with diuretic bumetanide: A proof-of-concept behavioral and functional brain imaging pilot study. Autism, 19(2), 149–157. https://doi.org/10.1177/1362361313514141CrossRefPubMed

Hage, A., Banaschewski, T., Buitelaar, J. K., Dijkhuizen, R. M., Franke, B., Lythgoe, D. J., & Dittmann, R. W. (2016). Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD)—study protocol for a randomised controlled trial. Trials, 17(1), 141. https://doi.org/10.1186/s13063-016-1266-8CrossRefPubMedPubMedCentral

Handen, B. L., Anagnostou, E., Aman, M. G., Sanders, K. B., Chan, J., Hollway, J. A., & Veenstra-VanderWeele, J. (2017). A Randomized, placebo-controlled trial of metformin for the treatment of overweight induced by antipsychotic medication in young people with autism spectrum disorder: Open-label extension. Journal of the American Academy of Child and Adolescent Psychiatry, 56(10), 849-856.e846. https://doi.org/10.1016/j.jaac.2017.07.790CrossRefPubMed

Handen, B. L., Johnson, C. R., & Lubetsky, M. (2000). Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders, 30(3), 245–255.CrossRef

Hardan, A. Y., Fung, L. K., Libove, R. A., Obukhanych, T. V., Nair, S., Herzenberg, L. A., & Tirouvanziam, R. (2012). A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biological Psychiatry, 71(11), 956–961. https://doi.org/10.1016/j.biopsych.2012.01.014CrossRefPubMedPubMedCentral

Hardan, A. Y., Hendren, R. L., Aman, M. G., Robb, A., Melmed, R. D., Andersen, K. A., & Graham, S. M. (2019). Efficacy and safety of memantine in children with autism spectrum disorder: Results from three phase 2 multicenter studies. Autism, 23(8), 2096–2111. https://doi.org/10.1177/1362361318824103CrossRefPubMedPubMedCentral

Hardan, A. Y., Jou, R. J., & Handen, B. L. (2005). Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. Journal of Autism and Developmental Disorders, 35(3), 387–391. https://doi.org/10.1007/s10803-005-3306-1CrossRefPubMed

Harfterkamp, M., van de Loo-Neus, G., Minderaa, R. B., van der Gaag, R. J., Escobar, R., Schacht, A., & Hoekstra, P. J. (2012). A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 51(7), 733–741. https://doi.org/10.1016/j.jaac.2012.04.011CrossRefPubMed

Hellings, J. A., Weckbaugh, M., Nickel, E. J., Cain, S. E., Zarcone, J. R., Reese, R. M., & Cook, E. H. (2005). A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 15(4), 682–692. https://doi.org/10.1089/cap.2005.15.682CrossRefPubMed

Herscu, P., Handen, B. L., Arnold, L. E., Snape, M. F., Bregman, J. D., Ginsberg, L., & Autism Speaks Autism Clinical Trials, N. (2020). The SOFIA study: Negative multi-center study of low dose fluoxetine on repetitive behaviors in children and adolescents with autistic disorder. Journal of Autism and Developmental Disorders, 50(9), 3233–3244. https://doi.org/10.1007/s10803-019-04120-yCrossRefPubMed

Hollander, E., Dolgoff-Kaspar, R., Cartwright, C., Rawitt, R., & Novotny, S. (2001). An open trial of divalproex sodium in autism spectrum disorders. The Journal of Clinical Psychiatry, 62(7), 530–534.CrossRef

Hollander, E., Phillips, A., Chaplin, W., Zagursky, K., Novotny, S., Wasserman, S., & Iyengar, R. (2005). A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology, 30(3), 582–589. https://doi.org/10.1038/sj.npp.1300627CrossRefPubMed

Hollander, E., Soorya, L., Chaplin, W., Anagnostou, E., Taylor, B. P., Ferretti, C. J., & Settipani, C. (2012). A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. The American Journal of Psychiatry, 169(3), 292–299. https://doi.org/10.1176/appi.ajp.2011.10050764CrossRefPubMed

Hollander, E., Wasserman, S., Swanson, E. N., Chaplin, W., Schapiro, M. L., Zagursky, K., & Novotny, S. (2006). A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. Journal of Child and Adolescent Psychopharmacology, 16(5), 541–548. https://doi.org/10.1089/cap.2006.16.541CrossRefPubMed

Jaselskis, C. A., Cook, E. H., Jr., Fletcher, K. E., & Leventhal, B. L. (1992). Clonidine treatment of hyperactive and impulsive children with autistic disorder. Journal of Clinical Psychopharmacology, 12(5), 322–327.CrossRef

Ji, N., & Findling, R. L. (2015). An update on pharmacotherapy for autism spectrum disorder in children and adolescents. Current Opinion in Psychiatry, 28(2), 91–101. https://doi.org/10.1097/yco.0000000000000132CrossRefPubMed

Jobski, K., Hofer, J., Hoffmann, F., & Bachmann, C. (2017). Use of psychotropic drugs in patients with autism spectrum disorders: A systematic review. Acta Psychiatrica Scandinavica, 135(1), 8–28. https://doi.org/10.1111/acps.12644CrossRefPubMed

Joshi, G., Wozniak, J., Faraone, S. V., Fried, R., Chan, J., Furtak, S., & Biederman, J. (2016). A Prospective open-label trial of memantine hydrochloride for the treatment of social deficits in intellectually capable adults with autism spectrum disorder. Journal of Clinical Psychopharmacology, 36(3), 262–271. https://doi.org/10.1097/jcp.0000000000000499CrossRefPubMed

Karhson, D. S., Hardan, A. Y., & Parker, K. J. (2016). Endocannabinoid signaling in social functioning: An RDoC perspective. Translational Psychiatry, 6(9), e905. https://doi.org/10.1038/tp.2016.169CrossRefPubMedPubMedCentral

Kim, S. J., Young, L. J., Gonen, D., Veenstra-VanderWeele, J., Courchesne, R., Courchesne, E., & Insel, T. R. (2002). Transmission disequilibrium testing of arginine vasopressin receptor 1A (AVPR1A) polymorphisms in autism. Molecular Psychiatry, 7(5), 503–507. https://doi.org/10.1038/sj.mp.4001125CrossRefPubMed

King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., & Ritz, L. (2009). Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: Citalopram ineffective in children with autism. Archives of General Psychiatry, 66(6), 583–590. https://doi.org/10.1001/archgenpsychiatry.2009.30CrossRefPubMedPubMedCentral

Kosaka, H., Okamoto, Y., Munesue, T., Yamasue, H., Inohara, K., Fujioka, T., & Wada, Y. (2016). Oxytocin efficacy is modulated by dosage and oxytocin receptor genotype in young adults with high-functioning autism: A 24-week randomized clinical trial. Translational Psychiatry, 6(8), e872. https://doi.org/10.1038/tp.2016.152CrossRefPubMedPubMedCentral

Kowalski, J. L., Wink, L. K., Blankenship, K., Habenicht, C. D., Erickson, C. A., Stigler, K. A., & McDougle, C. J. (2011). Paliperidone palmitate in a child with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 21(5), 491–493. https://doi.org/10.1089/cap.2011.0035CrossRefPubMedPubMedCentral

Kruppa, J. A., Gossen, A., Oberwelland Weiß, E., Kohls, G., Großheinrich, N., Cholemkery, H., & Schulte-Rüther, M. (2019). Neural modulation of social reinforcement learning by intranasal oxytocin in male adults with high-functioning autism spectrum disorder: A randomized trial. Neuropsychopharmacology, 44(4), 749–756. https://doi.org/10.1038/s41386-018-0258-7CrossRefPubMed

Kumar, B., Prakash, A., Sewal, R. K., Medhi, B., & Modi, M. (2012). Drug therapy in autism: a present and future perspective. Pharmacological Reports, 64(6), 1291–1304.CrossRef

Lamy, M., & Erickson, C. A. (2018). Pharmacological management of behavioral disturbances in children and adolescents with autism spectrum disorders. Current Problems in Pediatric and Adolescent Health Care, 48(10), 250–264. https://doi.org/10.1016/j.cppeds.2018.08.015CrossRefPubMed

Lamy, M., Pedapati, E. V., Dominick, K. L., Wink, L. K., & Erickson, C. A. (2020). Recent advances in the pharmacological management of behavioral disturbances associated with autism spectrum disorder in children and adolescents. Paediatric Drugs, 22(5), 473–483. https://doi.org/10.1007/s40272-020-00408-0CrossRefPubMed

Lemonnier, E., Degrez, C., Phelep, M., Tyzio, R., Josse, F., Grandgeorge, M., & Ben-Ari, Y. (2012). A randomised controlled trial of bumetanide in the treatment of autism in children. Translational Psychiatry, 2(12), e202. https://doi.org/10.1038/tp.2012.124CrossRefPubMedPubMedCentral

Lemonnier, E., Villeneuve, N., Sonie, S., Serret, S., Rosier, A., Roue, M., & Ben-Ari, Y. (2017). Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders. Translational Psychiatry, 7(3), e1056. https://doi.org/10.1038/tp.2017.10CrossRefPubMedPubMedCentral

Loebel, A., Brams, M., Goldman, R. S., Silva, R., Hernandez, D., Deng, L., & Findling, R. L. (2016). Lurasidone for the treatment of irritability associated with autistic disorder. Journal of Autism and Developmental Disorders, 46(4), 1153–1163. https://doi.org/10.1007/s10803-015-2628-xCrossRefPubMed

Logan, S. L., Carpenter, L., Leslie, R. S., Garrett-Mayer, E., Hunt, K. J., Charles, J., & Nicholas, J. S. (2015). Aberrant behaviors and co-occurring conditions as predictors of psychotropic polypharmacy among children with autism spectrum disorders. Journal of Child and Adolescent Psychopharmacology, 25(4), 323–336. https://doi.org/10.1089/cap.2013.0119CrossRefPubMedPubMedCentral

Logan, S. L., Nicholas, J. S., Carpenter, L. A., King, L. B., Garrett-Mayer, E., & Charles, J. M. (2012). High prescription drug use and associated costs among Medicaid-eligible children with autism spectrum disorders identified by a population-based surveillance network. Annals of Epidemiology, 22(1), 1–8. https://doi.org/10.1016/j.annepidem.2011.10.007CrossRefPubMedPubMedCentral

Lytle, S., McVoy, M., & Sajatovic, M. (2017). Long-acting injectable antipsychotics in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 27(1), 2–9. https://doi.org/10.1089/cap.2016.0055CrossRefPubMed

Maayan, L., & Correll, C. U. (2011). Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 21(6), 517–535. https://doi.org/10.1089/cap.2011.0015CrossRefPubMed

Malone, R. P., Cater, J., Sheikh, R. M., Choudhury, M. S., & Delaney, M. A. (2001). Olanzapine versus haloperidol in children with autistic disorder: An open pilot study. Journal of the American Academy of Child and Adolescent Psychiatry, 40(8), 887–894. https://doi.org/10.1097/00004583-200108000-00009CrossRefPubMed

Malow, B. A., Findling, R. L., Schroder, C. M., Maras, A., Breddy, J., Nir, T., & Gringras, P. (2021). Sleep, growth, and puberty after 2 years of prolonged-release melatonin in children with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 60(2), 252-261.e253. https://doi.org/10.1016/j.jaac.2019.12.007CrossRefPubMed

Maras, A., Schroder, C. M., Malow, B. A., Findling, R. L., Breddy, J., Nir, T., & Gringras, P. (2018). Long-term efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. Journal of Child and Adolescent Psychopharmacology, 28(10), 699–710. https://doi.org/10.1089/cap.2018.0020CrossRefPubMedPubMedCentral

Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., & Aman, M. G. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48(11), 1110–1119. https://doi.org/10.1097/CHI.0b013e3181b76658CrossRefPubMed

Marcus, R. N., Owen, R., Manos, G., Mankoski, R., Kamen, L., McQuade, R. D., & Findling, R. L. (2011). Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: A 52-week, open-label, multicenter study. Journal of Clinical Psychiatry, 72(9), 1270–1276. https://doi.org/10.4088/JCP.09m05933CrossRef

Martin, A., Koenig, K., Anderson, G. M., & Scahill, L. (2003). Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. Journal of Autism and Developmental Disorders, 33(1), 77–85.CrossRef

Martin, A., Koenig, K., Scahill, L., & Bregman, J. (1999). Open-label quetiapine in the treatment of children and adolescents with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 9(2), 99–107. https://doi.org/10.1089/cap.1999.9.99CrossRefPubMed

Mayes, S. D., Waxmonsky, J. G., Baweja, R., Mattison, R. E., Memon, H., Klein, M., & Waschbusch, D. (2020). Symptom scores and medication treatment patterns in children with ADHD versus autism. Psychiatry Research, 288, 112937. https://doi.org/10.1016/j.psychres.2020.112937CrossRefPubMed

McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., & McMahon, D. (2002). Risperidone in children with autism and serious behavioral problems. The New England Journal of Medicine, 347(5), 314–321. https://doi.org/10.1056/NEJMoa013171CrossRefPubMed

McDougle, C. J., Holmes, J. P., Carlson, D. C., Pelton, G. H., Cohen, D. J., & Price, L. H. (1998). A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Archives of General Psychiatry, 55(7), 633–641. https://doi.org/10.1001/archpsyc.55.7.633CrossRefPubMed

McDougle, C. J., Naylor, S. T., Cohen, D. J., Volkmar, F. R., Heninger, G. R., & Price, L. H. (1996). A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry, 53(11), 1001–1008.CrossRef

Ming, X., Gordon, E., Kang, N., & Wagner, G. C. (2008). Use of clonidine in children with autism spectrum disorders. Brain & Development, 30(7), 454–460. https://doi.org/10.1016/j.braindev.2007.12.007CrossRef

Mintz, M., & Hollenberg, E. (2019). Revisiting lithium: Utility for behavioral stabilization in adolescents and adults with autism spectrum disorder. Psychopharmacology Bulletin, 49(2), 28–40.PubMedPubMedCentral

Miral, S., Gencer, O., Inal-Emiroglu, F. N., Baykara, B., Baykara, A., & Dirik, E. (2008). Risperidone versus haloperidol in children and adolescents with AD : A randomized, controlled, double-blind trial. European Child & Adolescent Psychiatry, 17(1), 1–8. https://doi.org/10.1007/s00787-007-0620-5CrossRef

Muit, J. J., Bothof, N., & Kan, C. C. (2020). Pharmacotherapy of ADHD in adults with autism spectrum disorder: Effectiveness and side effects. Journal of Attention Disorders, 24(2), 215–225. https://doi.org/10.1177/1087054719866255CrossRefPubMed

Naaijen, J., Lythgoe, D. J., Amiri, H., Buitelaar, J. K., & Glennon, J. C. (2015). Fronto-striatal glutamatergic compounds in compulsive and impulsive syndromes: A review of magnetic resonance spectroscopy studies. Neuroscience & Biobehavioral Reviews, 52, 74–88. https://doi.org/10.1016/j.neubiorev.2015.02.009CrossRef

Nagaraj, R., Singhi, P., & Malhi, P. (2006). Risperidone in children with autism: Randomized, placebo-controlled, double-blind study. Journal of Child Neurology, 21(6), 450–455. https://doi.org/10.1177/08830738060210060801CrossRefPubMed

Ngamsamut, N., Hongkaew, Y., Vanwong, N., Srisawasdi, P., Puangpetch, A., Chamkrachangpada, B., & Sukasem, C. (2016). 9-Hydroxyrisperidone-induced hyperprolactinaemia in thai children and adolescents with autism spectrum disorder. Basic & Clinical Pharmacology & Toxicology, 119(3), 267–272. https://doi.org/10.1111/bcpt.12570CrossRef

Owada, K., Okada, T., Munesue, T., Kuroda, M., Fujioka, T., Uno, Y., & Yamasue, H. (2019). Quantitative facial expression analysis revealed the efficacy and time course of oxytocin in autism. Brain, 142(7), 2127–2136. https://doi.org/10.1093/brain/awz126CrossRefPubMed

Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., & Findling, R. L. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124(6), 1533–1540. https://doi.org/10.1542/peds.2008-3782CrossRefPubMed

Owens, J. A., Rosen, C. L., Mindell, J. A., & Kirchner, H. L. (2010). Use of pharmacotherapy for insomnia in child psychiatry practice: A national survey. Sleep Medicine, 11(7), 692–700. https://doi.org/10.1016/j.sleep.2009.11.015CrossRefPubMed

Owley, T., Salt, J., Guter, S., Grieve, A., Walton, L., Ayuyao, N., & Cook, E. H., Jr. (2006). A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16(5), 517–524. https://doi.org/10.1089/cap.2006.16.517CrossRefPubMed

Park, S. Y., Cervesi, C., Galling, B., Molteni, S., Walyzada, F., Ameis, S. H., & Correll, C. U. (2016). Antipsychotic use trends in youth with autism spectrum disorder and/or intellectual disability: A meta-analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 55(6), 456-468.e454. https://doi.org/10.1016/j.jaac.2016.03.012CrossRefPubMed

Parker, K. J., Oztan, O., Libove, R. A., Mohsin, N., Karhson, D. S., Sumiyoshi, R. D., & Hardan, A. Y. (2019). A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism. Science Translational Medicine, 11(491), 7356. https://doi.org/10.1126/scitranslmed.aau7356CrossRef

Parker, K. J., Oztan, O., Libove, R. A., Sumiyoshi, R. D., Jackson, L. P., Karhson, D. S., & Hardan, A. Y. (2017). Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism. Proceedings of the National Academy of Sciences of the United States of America, 114(30), 8119–8124. https://doi.org/10.1073/pnas.1705521114CrossRefPubMedPubMedCentral

Patra, S., Nebhinani, N., Viswanathan, A., & Kirubakaran, R. (2019). Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: A systematic review and meta-analysis. Autism Research, 12(4), 542–552. https://doi.org/10.1002/aur.2059CrossRefPubMed

Persico, A. M., Ricciardello, A., Lamberti, M., Turriziani, L., Cucinotta, F., Brogna, C., & Arango, C. (2021). The pediatric psychopharmacology of autism spectrum disorder: A systematic review—Part I: The past and the present. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 110, 110326. https://doi.org/10.1016/j.pnpbp.2021.110326CrossRef

Posey, D. J., Aman, M. G., McCracken, J. T., Scahill, L., Tierney, E., Arnold, L. E., & McDougle, C. J. (2007). Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: An analysis of secondary measures. Biological Psychiatry, 61(4), 538–544. https://doi.org/10.1016/j.biopsych.2006.09.028CrossRefPubMed

Posey, D. J., Guenin, K. D., Kohn, A. E., Swiezy, N. B., & McDougle, C. J. (2001). A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 11(3), 267–277. https://doi.org/10.1089/10445460152595586CrossRefPubMed

Pretzsch, C. M., Freyberg, J., Voinescu, B., Lythgoe, D., Horder, J., Mendez, M. A., & McAlonan, G. M. (2019a). Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. Neuropsychopharmacology, 44(8), 1398–1405. https://doi.org/10.1038/s41386-019-0333-8CrossRefPubMedPubMedCentral

Pretzsch, C. M., Voinescu, B., Mendez, M. A., Wichers, R., Ajram, L., Ivin, G., & McAlonan, G. M. (2019b). The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD). Journal of Psychopharmacology, 33(9), 1141–1148. https://doi.org/10.1177/0269881119858306CrossRefPubMed

Purkayastha, P., Malapati, A., Yogeeswari, P., & Sriram, D. (2015). A review on GABA/glutamate pathway for therapeutic intervention of ASD and ADHD. Current Medicinal Chemistry, 22(15), 1850–1859.CrossRef

Reeves, G. M., Keeton, C., Correll, C. U., Johnson, J. L., Hamer, R. M., Sikich, L., & Riddle, M. A. (2013). Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: Rationale, design, and methods. Child and Adolescent Mental Health, 7(1), 31. https://doi.org/10.1186/1753-2000-7-31CrossRef

Reichow, B., Volkmar, F. R., & Bloch, M. H. (2013). Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders. Journal of Autism and Developmental Disorders, 43(10), 2435–2441. https://doi.org/10.1007/s10803-013-1793-zCrossRefPubMedPubMedCentral

Rezaei, V., Mohammadi, M. R., Ghanizadeh, A., Sahraian, A., Tabrizi, M., Rezazadeh, S. A., & Akhondzadeh, S. (2010). Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Progress in Neuro-PsychopharMacology & Biological Psychiatry, 34(7), 1269–1272. https://doi.org/10.1016/j.pnpbp.2010.07.005CrossRef

Roke, Y., Buitelaar, J. K., Boot, A. M., Tenback, D., & van Harten, P. N. (2012). Risk of hyperprolactinemia and sexual side effects in males 10–20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. Journal of Child and Adolescent Psychopharmacology, 22(6), 432–439. https://doi.org/10.1089/cap.2011.0109CrossRefPubMed

Rossignol, D. A., & Frye, R. E. (2011). Melatonin in autism spectrum disorders: A systematic review and meta-analysis. Developmental Medicine & Child Neurology, 53(9), 783–792. https://doi.org/10.1111/j.1469-8749.2011.03980.xCrossRef

Rothärmel, M., Szymoniak, F., Pollet, C., Beherec, L., Quesada, P., Leclerc, S., & Guillin, O. (2018). Eleven years of clozapine experience in autism spectrum disorder: Efficacy and tolerance. Journal of Clinical Psychopharmacology, 38(6), 577–581. https://doi.org/10.1097/jcp.0000000000000955CrossRefPubMed

Sansone, S. M., Widaman, K. F., Hall, S. S., Reiss, A. L., Lightbody, A., Kaufmann, W. E., & Hessl, D. (2012). Psychometric study of the Aberrant Behavior Checklist in Fragile X Syndrome and implications for targeted treatment. Journal of Autism and Developmental Disorders, 42(7), 1377–1392. https://doi.org/10.1007/s10803-011-1370-2CrossRefPubMedPubMedCentral

Scahill, L., Aman, M. G., McDougle, C. J., McCracken, J. T., Tierney, E., Dziura, J., & Vitiello, B. (2006). A prospective open trial of guanfacine in children with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16(5), 589–598. https://doi.org/10.1089/cap.2006.16.589CrossRefPubMed

Scahill, L., Jeon, S., Boorin, S. J., McDougle, C. J., Aman, M. G., Dziura, J., & Vitiello, B. (2016). Weight gain and metabolic consequences of risperidone in young children with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 55(5), 415–423. https://doi.org/10.1016/j.jaac.2016.02.016CrossRefPubMedPubMedCentral

Scahill, L., McCracken, J. T., King, B. H., Rockhill, C., Shah, B., Politte, L., & McDougle, C. J. (2015). Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. American Journal of Psychiatry, 172(12), 1197–1206. https://doi.org/10.1176/appi.ajp.2015.15010055CrossRef

Schachter, H. M., Pham, B., King, J., Langford, S., & Moher, D. (2001). How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A Meta-Analysis. CMAJ, 165(11), 1475–1488.PubMedPubMedCentral

Schnider, P., Bissantz, C., Bruns, A., Dolente, C., Goetschi, E., Jakob-Roetne, R., & Grundschober, C. (2020). Discovery of balovaptan, a vasopressin 1a receptor antagonist for the treatment of autism spectrum disorder. Journal of Medicinal Chemistry, 63(4), 1511–1525. https://doi.org/10.1021/acs.jmedchem.9b01478CrossRefPubMed

Schoemakers, R. J., van Kesteren, C., van Rosmalen, J., Eussen, M., Dieleman, H. G., & Beex-Oosterhuis, M. M. (2019). No differences in weight gain between risperidone and aripiprazole in children and adolescents after 12 months. Journal of Child and Adolescent Psychopharmacology, 29(3), 192–196. https://doi.org/10.1089/cap.2018.0111CrossRefPubMed

Serret, S., Thümmler, S., Dor, E., Vesperini, S., Santos, A., & Askenazy, F. (2015). Lithium as a rescue therapy for regression and catatonia features in two SHANK3 patients with autism spectrum disorder: Case reports. BMC Psychiatry, 15, 107. https://doi.org/10.1186/s12888-015-0490-1CrossRefPubMedPubMedCentral

Sharma, A., & Shaw, S. R. (2012). Efficacy of risperidone in managing maladaptive behaviors for children with autistic spectrum disorder: A meta-analysis. Journal of Pediatric Health Care, 26(4), 291–299. https://doi.org/10.1016/j.pedhc.2011.02.008CrossRefPubMed

Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I., & Dunbar, F. (2004). Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114(5), e634-641. https://doi.org/10.1542/peds.2003-0264-FCrossRefPubMed

Siegel, M., Beresford, C. A., Bunker, M., Verdi, M., Vishnevetsky, D., Karlsson, C., & Smith, K. A. (2014). Preliminary investigation of lithium for mood disorder symptoms in children and adolescents with autism spectrum disorder. Journal of Child and Adolescent Psychopharmacology, 24(7), 399–402. https://doi.org/10.1089/cap.2014.0019CrossRefPubMed

Singh, K., Connors, S. L., Macklin, E. A., Smith, K. D., Fahey, J. W., Talalay, P., & Zimmerman, A. W. (2014). Sulforaphane treatment of autism spectrum disorder (ASD). Proceedings of the National Academy of Sciences of the United States of America, 111(43), 15550–15555. https://doi.org/10.1073/pnas.1416940111CrossRefPubMedPubMedCentral

Sochocky, N., & Milin, R. (2013). Second generation antipsychotics in Asperger’s Disorder and high functioning autism: A systematic review of the literature and effectiveness of meta-analysis. Current Clinical Pharmacology, 8(4), 370–379.CrossRef

Solimini, R., Rotolo, M. C., Pichini, S., & Pacifici, R. (2017). Neurological disorders in medical use of cannabis: An update. NS & Neurological DisordersDrug Targets, 16(5), 527–533. https://doi.org/10.2174/1871527316666170413105421CrossRef

Souders, M. C., Zavodny, S., Eriksen, W., Sinko, R., Connell, J., Kerns, C., & Pinto-Martin, J. (2017). Sleep in children with autism spectrum disorder. Current Psychiatry Reports, 19(6), 34. https://doi.org/10.1007/s11920-017-0782-xCrossRefPubMedPubMedCentral

Sprengers, J. J., van Andel, D. M., Zuithoff, N. P. A., Keijzer-Veen, M. G., Schulp, A. J. A., Scheepers, F. E., & Bruining, H. (2020). Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A single center, double-blinded, participant-randomized, placebo-controlled, phase-2 superiority trial. Journal of the American Academy of Child and Adolescent Psychiatry. https://doi.org/10.1016/j.jaac.2020.07.888CrossRefPubMed

Stigler, K. A., Mullett, J. E., Erickson, C. A., Posey, D. J., & McDougle, C. J. (2012). Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology (berl), 223(2), 237–245. https://doi.org/10.1007/s00213-012-2711-3CrossRef

Tordjman, S., Anderson, G. M., Pichard, N., Charbuy, H., & Touitou, Y. (2005). Nocturnal excretion of 6-sulphatoxymelatonin in children and adolescents with autistic disorder. Biological Psychiatry, 57(2), 134–138. https://doi.org/10.1016/j.biopsych.2004.11.003CrossRefPubMed

Translational Adolescent and Childhood Therapeutic Interventions in Compulsive Syndromes (TACTICS). (2018). Retrieved from November 26, 2018, from https://cordis.europa.eu/docs/results/278/278948/final1-01-tactics-final-publishable-report-final.pdf.

Troost, P. W., Lahuis, B. E., Steenhuis, M. P., Ketelaars, C. E., Buitelaar, J. K., van Engeland, H., & Hoekstra, P. J. (2005). Long-term effects of risperidone in children with autism spectrum disorders: A placebo discontinuation study. Journal of the American Academy of Child and Adolescent Psychiatry, 44(11), 1137–1144. https://doi.org/10.1097/01.chi.0000177055.11229.76CrossRefPubMed

Umbricht, D., Del Valle Rubido, M., Hollander, E., McCracken, J. T., Shic, F., Scahill, L., & Fontoura, P. (2017). A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a Receptor Antagonist (RG7713) in high-functioning adults with autism spectrum disorder. Neuropsychopharmacology, 42(9), 1914–1923. https://doi.org/10.1038/npp.2016.232CrossRefPubMed

van der Esch, C. C. L., Kloosterboer, S. M., van der Ende, J., Reichart, C. G., Kouijzer, M. E. J., de Kroon, M. M. J., & Dierckx, B. (2020). Risk factors and pattern of weight gain in youths using antipsychotic drugs. European Child & Adolescent Psychiatry. https://doi.org/10.1007/s00787-020-01614-4CrossRef

Varni, J. W., Handen, B. L., Corey-Lisle, P. K., Guo, Z., Manos, G., Ammerman, D. K., & Mankoski, R. (2012). Effect of aripiprazole 2 to 15 mg/d on health-related quality of life in the treatment of irritability associated with autistic disorder in children: A post hoc analysis of two controlled trials. Clinical Therapeutics, 34(4), 980–992. https://doi.org/10.1016/j.clinthera.2012.02.023CrossRefPubMed

Vasa, R. A., Carroll, L. M., Nozzolillo, A. A., Mahajan, R., Mazurek, M. O., Bennett, A. E., & Bernal, M. P. (2014). A systematic review of treatments for anxiety in youth with autism spectrum disorders. Journal of Autism and Developmental Disorders, 44(12), 3215–3229. https://doi.org/10.1007/s10803-014-2184-9CrossRefPubMed

Veenstra-VanderWeele, J., Cook, E. H., King, B. H., Zarevics, P., Cherubini, M., Walton-Bowen, K., & Carpenter, R. L. (2017). Arbaclofen in children and adolescents with autism spectrum disorder: A randomized, controlled, phase 2 trial. Neuropsychopharmacology, 42(7), 1390–1398. https://doi.org/10.1038/npp.2016.237CrossRefPubMed

Watanabe, T., Abe, O., Kuwabara, H., Yahata, N., Takano, Y., Iwashiro, N., & Yamasue, H. (2014). Mitigation of sociocommunicational deficits of autism through oxytocin-induced recovery of medial prefrontal activity: A randomized trial. JAMA Psychiatry, 71(2), 166–175. https://doi.org/10.1001/jamapsychiatry.2013.3181CrossRefPubMed

Watanabe, T., Kuroda, M., Kuwabara, H., Aoki, Y., Iwashiro, N., Tatsunobu, N., & Yamasue, H. (2015). Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism. Brain, 138(Pt 11), 3400–3412. https://doi.org/10.1093/brain/awv249CrossRefPubMed

Wink, L. K., Adams, R., Pedapati, E. V., Dominick, K. C., Fox, E., Buck, C., & Erickson, C. A. (2017). Brief report: Metformin for antipsychotic-induced weight gain in youth with autism spectrum disorder. Journal of Autism and Developmental Disorders, 47(7), 2290–2294. https://doi.org/10.1007/s10803-017-3132-2CrossRefPubMed

Wink, L. K., Adams, R., Wang, Z., Klaunig, J. E., Plawecki, M. H., Posey, D. J., & Erickson, C. A. (2016a). A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder. Molecular Autism, 7, 26. https://doi.org/10.1186/s13229-016-0088-6CrossRefPubMedPubMedCentral

Wink, L. K., Badran, I., Pedapati, E. V., Sorensen, R., Benton, S. C., Johnson, M. C., & Erickson, C. A. (2016b). Clozapine for drug-refractory irritability in individuals with developmental disability. Journal of Child and Adolescent Psychopharmacology, 26(9), 843–846. https://doi.org/10.1089/cap.2015.0216CrossRefPubMed

Wink, L. K., Early, M., Schaefer, T., Pottenger, A., Horn, P., McDougle, C. J., & Erickson, C. A. (2014a). Body mass index change in autism spectrum disorders: Comparison of treatment with risperidone and aripiprazole. Journal of Child and Adolescent Psychopharmacology, 24(2), 78–82. https://doi.org/10.1089/cap.2013.0099CrossRefPubMedPubMedCentral

Wink, L. K., O’Melia, A. M., Shaffer, R. C., Pedapati, E., Friedmann, K., Schaefer, T., & Erickson, C. A. (2014b). Intranasal ketamine treatment in an adult with autism spectrum disorder. Journal of Clinical Psychiatry, 75(8), 835–836. https://doi.org/10.4088/JCP.13cr08917CrossRef

Wink, L. K., Reisinger, D. L., Horn, P., Shaffer, R. C., O’Brien, K., Schmitt, L., & Erickson, C. A. (2021). Brief report: Intranasal ketamine in adolescents and young adults with autism spectrum disorder-initial results of a randomized, controlled, crossover, pilot study. Journal of Autism and Developmental Disorders, 51(4), 1392–1399. https://doi.org/10.1007/s10803-020-04542-zCrossRefPubMed

Yamasue, H., Okada, T., Munesue, T., Kuroda, M., Fujioka, T., Uno, Y., & Kosaka, H. (2020). Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: A randomized clinical trial. Molecular Psychiatry, 25(8), 1849–1858. https://doi.org/10.1038/s41380-018-0097-2CrossRefPubMed

Yang, S. Y., Cho, S. C., Yoo, H. J., Cho, I. H., Park, M., Yoe, J., & Kim, S. A. (2010). Family-based association study of microsatellites in the 5’ flanking region of AVPR1A with autism spectrum disorder in the Korean population. Psychiatry Research, 178(1), 199–201. https://doi.org/10.1016/j.psychres.2009.11.007CrossRefPubMed

Yasuhara, A. (2010). Correlation between EEG abnormalities and symptoms of autism spectrum disorder (ASD). Brain and Development, 32(10), 791–798. https://doi.org/10.1016/j.braindev.2010.08.010CrossRefPubMed

Yatawara, C. J., Einfeld, S. L., Hickie, I. B., Davenport, T. A., & Guastella, A. J. (2016). The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: A randomized clinical crossover trial. Molecular Psychiatry, 21(9), 1225–1231. https://doi.org/10.1038/mp.2015.162CrossRefPubMed

Yirmiya, N., Rosenberg, C., Levi, S., Salomon, S., Shulman, C., Nemanov, L., & Ebstein, R. P. (2006). Association between the arginine vasopressin 1a receptor (AVPR1a) gene and autism in a family-based study: Mediation by socialization skills. Molecular Psychiatry, 11(5), 488–494. https://doi.org/10.1038/sj.mp.4001812CrossRefPubMed

Yoon, Y., Wink, L. K., Pedapati, E. V., Horn, P. S., & Erickson, C. A. (2016). Weight gain effects of second-generation antipsychotic treatment in autism spectrum disorder. Journal of Child and Adolescent Psychopharmacology, 26(9), 822–827. https://doi.org/10.1089/cap.2016.0049CrossRefPubMed

Zamberletti, E., Gabaglio, M., & Parolaro, D. (2017). The endocannabinoid system and autism spectrum disorders: Insights from animal models. International Journal of Molecular Sciences, 18(9), 1916. https://doi.org/10.3390/ijms18091916CrossRefPubMedCentral

Zhang, L., Huang, C. C., Dai, Y., Luo, Q., Ji, Y., Wang, K., & Li, F. (2020). Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA/glutamate ratios. Translational Psychiatry, 10(1), 9. https://doi.org/10.1038/s41398-020-0692-2CrossRefPubMedPubMedCentral

Bohn Stafleu van Loghum

Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder

Abstract

Andere artikelen Uitgave 12/2021

Practice Patterns and Potential Barriers to Early Diagnosis of Autism in Bosnia and Herzegovina: A Preliminary Study

Exploring Predictors of Bullying and Victimization of Students with Autism Spectrum Disorder (ASD): Findings from NLTS 2012

Brief Report: Analysis of Dental Treatment Provided Under General Anaesthesia for Children and Young Adults with Autistic Spectrum Disorder and Identification of Challenges for Dental Services

Episodic Future Thinking in Autism Spectrum Disorder and 22q11.2 Deletion Syndrome: Association with Anticipatory Pleasure and Social Functioning

Correction to: The Adapted ADOS: A New Module Set for the Assessment of Minimally Verbal Adolescents and Adults

Profiles of Autonomic Activity in Autism Spectrum Disorder with and without Anxiety